Djalma Novaes Jr., Executive Vice President and Chief Operating Officer of Crown Holdings, Inc. (NYSE:CCK), executed a sale of 29,734 shares of the company's common stock on February 23, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $114.80 apiece, producing proceeds of roughly $3.4 million.
Following the disposition, Novaes retains direct ownership of 88,052 shares of Crown Holdings stock. The sale occurred with Crown trading close to its 52-week high of $115.85 and after the share price rose approximately 34% over the prior 12 months.
On valuation metrics cited alongside the filing, the company is shown with a market value of about $12.9 billion, a price-to-earnings ratio of 18.01 and a price/earnings-to-growth ratio of 0.22.
Independent research commentary included in public data noted that the stock is assessed as undervalued against a Fair Value benchmark and that Crown Holdings carries a "GREAT" financial health score. The noted research is part of a broader set of subscription Pro Research materials and ProTips available through a market research service.
Analyst coverage since the transaction has been varied. RBC Capital Markets raised its price target on Crown to $140 from $120 and kept an Outperform rating, citing the company’s steady execution and a run of results that have topped expectations. RBC highlighted that Crown has beaten expectations for eight consecutive quarters and expects North American volume growth in the 2-3% range, with earnings growth improving in fiscal 2027.
Jefferies reiterated a Buy rating and set a price target of $142 after hosting analysts and investors on a field visit to one of Crown’s advanced beverage can plants in North America.
By contrast, UBS moved its rating down from Buy to Neutral and assigned a $126 price target, pointing to expectations for more moderate earnings growth. Wolfe Research downgraded Crown from Outperform to Peerperform, describing the stock as presenting a more balanced risk/reward profile following a period of material fundamental improvement, including deleveraging efforts.
JPMorgan also reduced its stance from Overweight to Neutral, even as it nudged its price target higher to $115 from $112, citing valuation concerns after the company’s notable share-price advance.
Collectively, the analyst actions represent a mix of bullishness — reflected in higher price targets and continued Outperform/Buy ratings — and caution, shown by multiple downgrades tied to valuation and expectations for future earnings moderation.
Investors tracking insider activity and analyst signals will note that the executive sale occurred while the stock trades near its yearly peak and amid divergent professional views on near-term growth and valuation. The filing provides a clear record of the transaction and Novaes’ remaining stake; the accompanying analyst commentary frames a market debate between ongoing operational strength and concerns over stock valuation.